Focusing on the tumor microenvironment, OncoResponse garners $40 million for the next stage of the R&D journey
OncoResponse has entered the on-ramp for its immuno-oncology clinical plans. And the biotech now has a $40 million B round from a mix of mainstream …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
